- Policy
- Handok paces its efforts to reimburse Pivlaz in KOR
- by Lee, Tak-Sun Jun 11, 2024 05:47am
- Handok is taking a break from its pursuit of reimbursement for ‘Pivlaz,’ a new drug used to prevent cerebral vasospasm in patients with subarachnoid hemorrhage that the company is supplying and distributing in Korea. The company immediately applied for Pivlaz’s reimbursement to the Health Insurance Review and Assessment Service after
- Policy
- Roche applies for Ocrevus' reimbursement in KOR
- by Lee, Tak-Sun Jun 10, 2024 05:41am
- Roche Korea applied for reimbursement of 'Ocrevus Inj. (ocrelizumab, Roche Korea),’ its multiple sclerosis treatment that was approved last month, to the Health Insurance Review and Assessment Service. The drug is administered twice a year, which is considered to have dramatically improved the dosing convenience for MS patients. The d
- Policy
- Latuda·Dupixent enter negotiations with the NHIS
- by Lee, Tak-Sun Jun 7, 2024 05:50am
- 'Latuda (lurasidone),' a medication used to treat schizophrenia and imported and distributed by Bukwang Pharmaceutical, and 'Dupixent (dupilumab),' which aims to expand reimbursement for young children, have entered negotiations with the National Health Insurance Service (NHIS). When an agreement with the National Health Insurance Service
- Policy
- Gov’t will maintain criteria for KIPC recertifications
- by Lee, Jeong-Hwan Jun 5, 2024 05:47am
- The government has decided to maintain the recertification process and criteria for Korea Innovative Pharmaceutical Companies. Therefore, the government decided not to accept the demands of some in the pharmaceutical industry on easing the decertification regulations, ‘2 or more rebate detections and administrative disposition’, and t
- Policy
- Lorviqua fails to receive reimb as first-line therapy
- by Lee, Tak-Sun Jun 4, 2024 05:47am
- The reimbursement extension application for Lorviqua, a treatment for anaplastic lymphoma kinase (ALK)-positive non-small-cell cancer, &160;has failed to go beyond the negotiation stage with the National Health Insurance Service. With the breakdown of the negotiations, the company will have to start over from the application stage for Lo
- Policy
- Takeda’s Zejula Tab receives marketing authorization in KOR
- by Lee, Hye-Kyung Jun 3, 2024 05:49am
- Takeda Pharmaceuticals’ poly ADP-ribose polymerase Inhibitor ‘Zejual (niraparib)’ has been granted marketing authorization in Korea in its tablet form. The Ministry of Food and Drug Safety (MFDS) approved Zejula Tab 100 mg on the 31st. Like its capsule formulation, Zejula Tab is indicated ▲as monotherapy for adult patients with ova
- Policy
- Qarziba’s reimb standard has been set before approval
- by Lee, Tak-Sun May 31, 2024 05:51am
- The reimbursement standard has been set for Qarziba (dinutuximab, Recordati Korea), which was designated as the 1st drug for a “Pilot Project for Integration of Product Approvals, Reimbursement Coverage Reviews, and Drug Price Negotiations,” even though it has not yet received approval from the Ministry of Food and Drug Safety (MFDS). Qarzi
- Policy
- MFDS approves the orphan drug 'Pluvicto' for prostate cancer
- by Lee, Hye-Kyung May 31, 2024 05:51am
- The Ministry of Food and Drug Safety (MFDS) stated that on May 29th, it has granted approval of the orphan drug 'Pluvicto inj (Lutetium(177Lu) Vipivotide Tetraxetan)' for the treatment of prostate cancer. Pluvicto is imported by Novartis Korea. It is a radioligand therapy comprised of radioisotope Lutetium(177Lu), which binds to prostate
- Policy
- Korea-US gov't pledge to strengthen biohealth cooperation
- by Lee, Jeong-Hwan May 31, 2024 05:51am
- The Korean government has decided to strengthen cooperation with the U.S. Department of Commerce in the field of telemedicine and digital health, including non-face-to-face medical treatment. CareLabs and Lulu Medic, Korea’s leading healthcare platforms including domestic non-face-to-face treatment applications, Teladoc, the No. 1 teleme
- Policy
- Research on reforming post-management of pharmaceuticals
- by Lee, Tak-Sun May 30, 2024 05:50am
- The government has initiated research on developing a comprehensive reform of post-insurance management of pharmaceuticals. This research was part of the 2nd Comprehensive NHI Plan, announced earlier this year. According to industry sources on May 29th, a policy initiative reporting session was held to announce the start of the res
